Back to top

BioCryst Pharmaceuticals, Inc. (BCRX) Enters Overbought Territory
August 08, 2013

Read MoreHide Full Article

BioCryst Pharmaceuticals, Inc. (BCRX - Free Report) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because BCRX is now in overbought territory with an RSI value of 84.76. Furthermore, estimates for the BioCryst Pharmaceuticals have been coming down, pushing it to a Zacks Rank #4 (Sell). This suggests that investors may better off exiting this stock before it falls back to Earth.




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


BioCryst Pharmaceuticals, Inc. (BCRX) - free report >>


More from Zacks Tale of the Tape

You May Like